Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
NewsUpdated Report an error

Enspryng Is Approved for Thyroid Eye Disease as the First At-Home Shot, With 1 Trial Won and 1 Lost

The FDA approved Enspryng (satralizumab) for thyroid eye disease, Genentech and Roche announced on October 16, 2026, making it the first treatment people can inject at home. Of its 2 identical Phase 3 trials, SatraGO-2 met its goal and SatraGO-1 missed. This guide shows why the twins split, what the FDA has done with 1 positive trial before, how a monthly shot at home sits against the 8 and 5 infusions of Tepezza and Lumvoa, and what the label says.

Close-up of a woman's hazel eyes looking upward, dark curls blurred around her face.

Enspryng, a monthly shot that patients give themselves at home, became the third approved drug for thyroid eye disease and the first that is not an infusion when the FDA approved it on October 15, 2026, its target date. Genentech and Roche announced the approval the next day. The approval was unusual because the evidence was split down the middle. Genentech ran 2 trials built to the same blueprint, SatraGO-1 and SatraGO-2, in 258 people across 19 countries. One met its goal. The other did not. The company filed anyway, the FDA accepted the application with priority review, and 5 days before that acceptance was announced, the FDA had published a revised draft of its guidance for this kind of split.

The twin trials: same drug, same design, 2 verdicts
Share of people with active, moderate-to-severe thyroid eye disease whose eye bulging (proptosis) improved by at least 2mm at week 24. Both trials were double-masked and placebo-controlled; the primary analysis counted only the active-disease patients.
SatraGO-1
NCT05987423, 131 enrolled, 46 sites, 11 in the US
MISSED
p = 0.0715. The 17.9-point gap did not reach statistical significance. Average bulging fell 1.48mm on Enspryng and 1.31mm on placebo, almost the same.
SatraGO-2
NCT06106828, 127 enrolled, 41 sites, 6 in the US
MET
p = 0.0011. A 28.9-point gap, with average bulging down 1.97mm on Enspryng against 0.96mm on placebo.

Results posted on ClinicalTrials.gov (July 31 and August 12, 2026) and published in Ophthalmology, 2026. Look at the 2 drug bars first: 49% and 53%, nearly identical. Then the placebo bars: 31% and 23%. The trial that failed is the one where placebo did unusually well.

What SatraGO-2 Proved About Enspryng in Thyroid Eye Disease

Thyroid eye disease is the autoimmune complication of Graves' disease in which the immune system inflames the fat and muscle behind the eyes, pushing the eyeballs forward, pulling the lids back and, in the worst cases, pinching the optic nerve. It affects somewhere between 90 and 300 people per 100,000 (NORD, 2024), and about half of people with an overactive thyroid get at least a mild form (Genentech, 2026). The active, inflamed phase lasts 6 months to 2 years before the disease burns out and leaves whatever damage it has done. Every drug trial in the field measures the same thing: how many patients see their eye bulging shrink by at least 2 millimeters, usually at week 24 (Lumvoa's trials used week 15), without the other eye getting worse.

By that measure SatraGO-2 was a clean win. In 48 people with active disease on Enspryng, 52.9% were responders against 23.4% of 49 on placebo, a gap of 28.9 points that would appear about 1 time in 900 if the drug did nothing (p = 0.0011). The secondary measures lined up behind it: 89.6% had their clinical activity score, the 7-point inflammation scale doctors use, fall by at least 2 points against 63.3% on placebo, 68.8% reached an inactive score of 0 or 1 against 40.8%, and 60.7% had their double vision improve by at least 1 grade against 25.8%. Average bulging dropped 1.97mm on the drug and 0.96mm on placebo (ClinicalTrials.gov NCT06106828).

The drug reached these numbers by a different road than the 2 approved treatments. Tepezza and Lumvoa block IGF-1R, a growth receptor on the orbital fibroblasts that swell the tissue behind the eye. Enspryng blocks the receptor for interleukin-6, an inflammatory messenger whose blood levels track with disease activity in thyroid eye disease and which drives the production of the thyroid-stimulating antibodies that start the whole process. The idea had been tested before Genentech got there: a 32-patient Spanish trial of tocilizumab, an older IL-6 receptor antibody, found that 93% of steroid-resistant patients had their inflammation score fall by 2 points against 59% on placebo (Perez-Moreiras et al., American Journal of Ophthalmology, 2018). Enspryng is tocilizumab's engineered descendant, built by Chugai with a "recycling" design that lets each antibody molecule bind the receptor repeatedly, which Genentech says gives sustained IL-6 inhibition.

Why SatraGO-1 Missed, and What a 31% Placebo Response Means

SatraGO-1 enrolled the same kind of patient, used the same weight-tiered doses of 60, 120 or 180mg at weeks 0, 2 and 4 and then every 4 weeks, and measured the same endpoint. Among 50 people on Enspryng, 49.0% were responders. Among 51 on placebo, 31.2% were. The 17.9-point gap carried a p-value of 0.0715, which is to say about a 7 in 100 chance that a difference that size could appear with a drug that does nothing, and the FDA's conventional line is 5 in 100 (ClinicalTrials.gov NCT05987423).

Genentech has not offered an explanation, and the posted data point to a plausible one that they cannot confirm. Enspryng performed almost identically in the 2 trials, 49% and 53%. Placebo did not: 31% in SatraGO-1 against 23% in SatraGO-2, and 20% and 10% in the 2 Tepezza trials, 5% and 8% in Lumvoa's. Thyroid eye disease improves on its own as the active phase ends, so if a trial happens to enroll people slightly later in that phase, or with milder swelling to begin with, it will see more placebo responders and a smaller gap; the posted results do not report the baseline differences that would settle whether that happened here. The average-change numbers say the same thing in a different way: on Enspryng, bulging fell 1.48mm in SatraGO-1 and 1.97mm in SatraGO-2, but on placebo it fell 1.31mm in the first trial and only 0.96mm in the second. The drug effect was there both times. The comparison group moved.

The miss was not total. In SatraGO-1 the inflammation score still fell by 2 or more points in 78.0% of Enspryng patients against 54.9% on placebo (p = 0.0120), 68.0% reached an inactive score against 45.1% (p = 0.0146), and when the trial's inactive-disease patients were added to the count, the proptosis response was 47.1% against 25.4% (p = 0.0070). Double vision did not separate, 44.4% against 34.4%. Genentech's press release uses a specific phrase for all of this: SatraGO-1 "offers additional confirmatory evidence." The phrase echoes the vocabulary of the FDA rule that decides the case.

Latest for Thyroid Eye Disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Want the next Thyroid Eye Disease update without checking back?

We email you when a new Thyroid Eye Disease trial opens or an FDA decision comes out.

You'll get trial alerts and disease updates for Thyroid Eye Disease, and you can turn either off anytime. We never share your email. Privacy policy

What the FDA Does With One Positive Trial of Two

The law has asked for "substantial evidence" of effectiveness since the 1962 drug amendments, and for decades the agency read that as 2 adequate and well-controlled trials. Congress loosened it in 1997 so that the standard "could also be met by a single trial plus confirmatory evidence," and the FDA's December 2019 draft guidance on the subject set out when 1 trial is enough, adding that "the degree of certainty supporting such a conclusion may differ, depending on clinical circumstances (e.g., severity and rarity of the disease and unmet medical need)" (Federal Register, December 20, 2019). A 2023 draft went further into what counts as confirmatory evidence, and on June 24, 2026, 5 days before Genentech announced that the FDA had accepted the Enspryng application, the FDA published a revised draft of the 2019 guidance that leans harder on the single-trial path.

Precedent cuts both ways. Tepezza itself was approved in January 2020 on 1 Phase 3 trial of 83 people plus a Phase 2 trial with a different primary endpoint, and an advisory committee voted 12 to 0 for it. The cautionary case is Aduhelm, the Alzheimer's antibody whose 2 twin trials split the same way, EMERGE positive and ENGAGE negative; the FDA approved it in June 2021 over its advisers' objections, on an accelerated pathway tied to a biomarker rather than on the clinical result, and Biogen discontinued it in 2024, saying the decision was not related to safety or efficacy. Enspryng's application sought traditional approval rather than accelerated approval, measured on eye bulging rather than a surrogate, which made the question cleaner: did a strongly positive trial plus a trial that pointed the same way on every inflammation measure add up to substantial evidence? Priority review put the application on a 6-month clock rather than 10, and on October 15th the answer was yes.

One drug, 3 diseases, 2 decisions 3 months apart
Enspryng's regulatory life drawn to scale. Bars are trials from first patient to posted results; ringed nodes are FDA actions.
NMOSD
neuromyelitis optica
1
2
Thyroid eye disease
SatraGO program
SatraGO-1, 131 patients, missed
SatraGO-2, 127 patients, met
3
4
5
MOGAD
MOG antibody disease
METEOROID, relapses cut 68%
6
7
NMOSD
  1. Aug 2020 FDA approval, first self-injected NMOSD drug
  2. Jun 2026 Autoinjector added
Thyroid eye disease
  1. Oct 2025 Twin results presented, 1 met, 1 missed
  2. Jun 2026 FDA accepts filing, priority review
  3. Oct 2026 FDA approval
MOGAD
  1. Sep 2026 FDA accepts filing
  2. Jan 2027 FDA decision due
FDA approvalFDA decision dueSetback or mixed resultFiling or label changeTrial, first patient to results

Dates from Genentech press releases and ClinicalTrials.gov. The ASOPRS presentation is placed in mid-October 2025; the meeting ran that month and Genentech gives no exact day. METEOROID's bar runs from its registered start to its primary completion date (NCT05271409).

Enspryng Against Tepezza and Lumvoa, Shot by Shot

The comparison patients will actually make is not against placebo. It is against the 2 drugs that were already on the shelf, and on the headline number Enspryng's trials reported lower responder rates. In its pivotal trial Tepezza turned 83% of active-disease patients into proptosis responders against 10% on placebo, a 73-point gap; its Phase 2 trial found 71% against 20%. Lumvoa, approved June 26, 2026, reported 70% against 5% in active disease and 57% against 8% in chronic disease. Enspryng's 2 trials found 49% and 53%. No trial has compared the drugs directly, the placebo groups behaved very differently, and a responder rate is a crude yardstick, but in their own trials the IGF-1R drugs reported larger responder rates on eye bulging.

Proptosis responder rate, drug versus placebo, in every pivotal trial of an approved or filed thyroid eye disease drug
Hot dot is the drug, grey dot is placebo, the bar is the gap. Trials used the same 2mm endpoint but different patients and years, so this is a yardstick, not a ranking.
Tepezza, OPTIC
Active TED, 41 vs 42, reported 2019
83%10%73-point gap
Tepezza, Phase 2
Active TED, 42 vs 45, reported 2017
71%20%51-point gap
Lumvoa, THRIVE
Active TED, 75 vs 38, week 15
70%5%65-point gap
Lumvoa, THRIVE-2
Chronic TED, 125 vs 63, week 15
57%8%49-point gap
Enspryng, SatraGO-2
Active TED, 48 vs 49, week 24
52.9%23.4%28.9-point gap
Enspryng, SatraGO-1
Active TED, 50 vs 51, week 24
49.0%31.2%17.9-point gap, not significant
DrugPlacebo

Tepezza and Lumvoa figures from their FDA labels; Enspryng figures from ClinicalTrials.gov. Lumvoa's responder rate was measured at week 15, the others at week 24. Note that Enspryng's placebo groups responded 2 to 6 times as often as the placebo groups in the 3 Phase 3 IGF-1R trials (10%, 5% and 8%), which shrinks its gap even where the drug response is similar.

The other half of the comparison is what each drug asks of the patient. Tepezza is 8 intravenous infusions of 60 to 90 minutes, every 3 weeks for about 5 months, in an infusion center. Lumvoa is 5 infusions over 12 weeks. Enspryng is a prefilled syringe or autoinjector that a patient or caregiver injects under the skin at home after training, with a loading series at weeks 0, 2 and 4 and then a dose every 4 weeks; in the thyroid eye disease trials that meant 7 injections in the first 24 weeks. Roche makes the point directly, calling Enspryng "the first and only at-home subcutaneous treatment option" for the disease in its approval announcement.

A course of treatment for active thyroid eye disease, visit by visit
Doses in the trial or label regimen that produced the responder rates above. Tepezza and Lumvoa are clinic infusions; Enspryng is self-injected under the skin. Schedules from the Tepezza and Lumvoa labels and the SatraGO trial records; in the trials Enspryng continued every 4 weeks past week 24, so a full course may run longer than 7 doses.
Tepezzateprotumumab, approved 20208 infusions
Infusion center, every 3 weeks, 60 to 90 minutes eachA first dose of 10mg/kg then 20mg/kg for 7 more; about 21 weeks from first to last.
Lumvoaveligrotug, approved June 20265 infusions
Infusion center, every 3 weeks, 30 to 45 minutes eachEach dose is 10mg/kg; 12 weeks from first to last.
Enspryngsatralizumab, approved October 20267 injections
At home, self-injected after trainingWeeks 0, 2 and 4, then every 4 weeks; the label dose is 120mg, or 180mg above 100kg of body weight. Trial doses were 60, 120 or 180mg by weight.

The Hearing Warning That Follows IGF-1R Drugs and Not Enspryng

The strongest argument for Enspryng is not on the efficacy chart. Both IGF-1R drugs carry a warning that they "may cause severe hearing impairment including hearing loss, which in some cases may be permanent." On Tepezza's label, hearing problems affected 10% of patients in the pivotal trials and 19% in 2 trials run after approval, and the warning was added in July 2023, more than 3 years after approval. Lumvoa's label, from its first day, reports hearing impairment in 15% of patients against 6% on placebo, plus muscle spasms in 40%, raised blood sugar in 13%, and menstrual changes in 29% of women. Both drugs block the same receptor, and the hearing warning has followed the class.

Enspryng has 6 years of use in NMOSD and more than 16,000 treated patients behind it, by Roche's count, and its warnings are the ones that come with blocking IL-6: infections including serious ones, raised liver enzymes that need checking every 4 weeks for the first 3 months, lowered neutrophil counts, and hypersensitivity. Patients are screened for hepatitis B and tuberculosis before the first dose and cannot have live vaccines. In the SatraGO trials through week 24, serious adverse events occurred in 4.5% and 3.1% of Enspryng patients against 3.2% and 4.8% on placebo, with no deaths and no serious infections; SatraGO-2 did see more liver enzyme rises (6 against 1 for ALT) and more low neutrophil counts (4 against 1). Nothing about hearing appears in the adverse event tables of either trial, and the label approved for thyroid eye disease in October 2026 added no hearing warning. For a patient who is a musician, a teacher, or already hard of hearing, that difference may matter more than 20 points of responder rate.

Tepezza and Lumvoa (IGF-1R blockers)
Larger trial responder rates, hearing warning
Responder rates of 70-83% in active disease. Both labels warn of possibly permanent hearing loss (10-19% on Tepezza across trials, 15% on Lumvoa), plus muscle spasms, high blood sugar and menstrual disruption. Hearing is checked before, during and after treatment.
Enspryng (IL-6 receptor blocker)
Smaller trial responder rates, no hearing warning
Responder rates of 49% and 53%, 1 of 2 trials significant. Warnings are infection, liver enzymes and neutrophils, all monitored by blood test. No hearing adverse events reported in either trial, and 6 years of NMOSD use without a hearing warning.

How the Enspryng Decision Compared With the 3 Outcomes Mapped Before It

Three ways the Enspryng decision could have gone
Mapped before the October 15th action date from the shape of the application, with what each outcome would have meant for a patient deciding on treatment. The FDA took the first branch, with a piece of the second.
  1. Approved for active thyroid eye disease
    For youA third option, and the first that can be taken at home without an infusion chair or a hearing test. It would likely be chosen first by people who cannot risk hearing loss, who live far from an infusion center, or who want to avoid IGF-1R side effects, and second by those who want the biggest change in eye bulging.
    SignsThe FDA's June 2026 guidance revision, priority review, a drug with a long safety record, and SatraGO-1 pointing the same direction on every inflammation measure all favored this.
  2. Approved with a narrower label or extra conditions
    For youThe same drug, but the label might restrict it to the SatraGO-2 population, require a confirmatory study, or describe the SatraGO-1 result plainly in the clinical studies section so that doctors see the split. In practice insurers would use that language to decide who gets covered.
    SignsThis is the usual compromise when 1 of 2 trials misses and the agency is persuaded by the whole picture but not by both trials.
  3. Complete response letter
    For youNo change to the options patients had. Genentech could run a third trial or resubmit with more data from the trials' second phase, which ran to week 72, pushing any approval into 2028 or later. Enspryng would still be prescribable off-label, as tocilizumab already is, though insurers generally do not cover off-label use.
    SignsThe agency can reject an application in this position; a reviewer who weighs the SatraGO-1 proptosis miss over the inflammation wins would land here.

The same drug faces a second FDA decision on January 10, 2027 for MOG antibody-associated disease, where it cut relapses by 68% in its Phase 3 trial, so Enspryng will be back in the news within 3 months.

The FDA took the first branch with a piece of the second. The label covers adults with thyroid eye disease regardless of how active it is or how long it has lasted, broader than the active disease both trials' primary analyses measured, and its clinical studies section states plainly that SatraGO-1 did not meet its primary endpoint. Anyone reading the label can see the split, and its wording does not exclude people with chronic disease. Roche says SatraGO-2's results held up when people with chronic disease were counted alongside those with active disease.

The field kept moving under the approval. Viridian's elegrobart, an under-the-skin IGF-1R antibody, has already posted 2 positive Phase 3 trials (54-63% responders against 18% in active disease) and is headed for its own filing in the first quarter of 2027, and Amgen's on-body subcutaneous version of Tepezza hit 76.7% against 19.6% in its Phase 3. Within 2 years the at-home advantage Enspryng launched with may belong to 3 drugs. What stays Enspryng's alone is the mechanism and the absence of a hearing warning.

Thyroid Eye Disease Clinical Trials Recruiting Now

The SatraGO trials are complete, so Enspryng for thyroid eye disease now comes by prescription rather than through a study. The recruiting pipeline as of October 2026 is thinner than the number of drugs suggests, because 2 of the most-watched programs ended: Immunovant reported that batoclimab missed its primary endpoint in both Phase 3 trials, and argenx said it stopped its 2 efgartigimod trials for futility in December 2025, although it has since registered 2 new Phase 3 studies, 1 of them at 21 US sites (NCT07570316). Sling Therapeutics started the Phase 3 trial of linsitinib, an oral IGF-1R blocker, in August 2026 (NCT07753603). The thyroid eye disease trials page lists what is recruiting, and the trials near me tool maps the sites.

Genentech Access Solutions, the company's support program, checks insurance benefits and helps with prior authorization. A Genentech co-pay program helps commercially insured patients, and the Genentech Patient Foundation gives the medicine free to people without insurance or with financial concerns who meet its income rules. Trial Friend's help paying page lists what each one covers.

See the Enspryng approval details
The FDA calendar page for this decision has the approval and the label dose, and the calendar tracks the January 10, 2027 MOGAD decision next.
Open the decision page
Get the next Thyroid Eye Disease update by email

One email when Thyroid Eye Disease trials change or an FDA decision lands. No newsletter, no spam.

You'll get, for Thyroid Eye Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Questions People Ask About Enspryng for Thyroid Eye Disease

Is Enspryng FDA approved for thyroid eye disease?

Yes. The FDA approved Enspryng on October 15, 2026, its target date, and Genentech and Roche announced it the next day. The label covers adults with thyroid eye disease regardless of how active the disease is or how long it has lasted. The FDA had accepted the application on June 29, 2026 with priority review, which shortens the review to about 6 months.

Did Enspryng work in the thyroid eye disease trials?

In 1 of 2. In SatraGO-2, 52.9% of patients with active disease had their eye bulging improve by at least 2mm at week 24 against 23.4% on placebo, a significant result. In SatraGO-1 it was 49.0% against 31.2%, which did not reach statistical significance because the placebo group did unusually well. Inflammation scores fell significantly on the drug in both trials.

Is Enspryng better than Tepezza for thyroid eye disease?

No trial has compared them, so neither can be called better. On eye bulging, Tepezza's pivotal trial had 83% responders against 10% on placebo, while Enspryng's trials had 49% and 53% against 31% and 23%. On convenience and hearing, the labels differ: it is a self-injected shot every 4 weeks rather than 8 clinic infusions, and its trials reported no hearing problems, while Tepezza's label warns of possibly permanent hearing loss. The 2 drugs have never been compared in the same trial.

How is Enspryng given?

Enspryng is an injection under the skin from a prefilled syringe or autoinjector, given at weeks 0, 2 and 4 and then every 4 weeks, and patients or caregivers can inject it at home after training. For thyroid eye disease the label dose is 120mg for people who weigh 40 to 100kg and 180mg for people over 100kg. In the trials the dose was 60, 120 or 180mg depending on body weight.

Does Enspryng cause hearing loss like Tepezza?

No hearing problems were reported in either SatraGO trial, and Enspryng's label, including the October 2026 version that added thyroid eye disease, carries no hearing warning. Its warnings are infections, raised liver enzymes, low neutrophil counts and allergic reactions. Tepezza and Lumvoa both block IGF-1R, and both labels warn of hearing loss that can be permanent.

Can the FDA approve a drug when one of two trials failed?

Yes. Since 1997 the law has allowed approval on 1 adequate and well-controlled trial plus confirmatory evidence, and the FDA reissued its guidance on that path on June 24, 2026. Tepezza was approved on 1 Phase 3 trial plus a Phase 2. The FDA has also rejected applications in this position, and Aduhelm, approved in 2021 after 1 of its 2 twin trials failed, was discontinued by Biogen in 2024 for reasons the company said were unrelated to safety or efficacy. Enspryng's October 2026 approval is a new example; Genentech and Roche said it rests on the totality of data from both trials.

What drugs are approved for thyroid eye disease in 2026?

Three. Tepezza (teprotumumab), approved January 21, 2020, and Lumvoa (veligrotug), approved June 26, 2026, are infusions that block IGF-1R, and both carry a hearing-loss warning. Enspryng (satralizumab), approved in October 2026, blocks the IL-6 receptor instead, is injected under the skin at home, and has no hearing warning.

Is Enspryng approved for anything else?

Yes. The FDA approved it on August 14, 2020 for adults with neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive, and it is approved in about 90 countries for that use. A separate FDA decision for MOG antibody-associated disease is due January 10, 2027.

Know someone this would help?

Sources

FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
F. Hoffmann-La Roche via GlobeNewswire · 2026-10-16
Enspryng supplemental BLA 761149/S-008 approval letter (thyroid eye disease)
U.S. Food and Drug Administration · 2026-10-15
Enspryng (satralizumab-mwge) prescribing information, revised 10/2026
U.S. Food and Drug Administration
Enspryng (satralizumab-mwge) injection: prescribing information, revised October 2026 to add thyroid eye disease
Genentech
FDA grants priority review to Genentech's Enspryng for thyroid eye disease
Genentech · 2026-06-29
SatraGO-1: a Phase III study of satralizumab in participants with moderate-to-severe thyroid eye disease (NCT05987423), posted results
ClinicalTrials.gov · 2026-07-31
SatraGO-2: a Phase III study of satralizumab in participants with moderate-to-severe thyroid eye disease (NCT06106828), posted results
ClinicalTrials.gov · 2026-08-12
Efficacy and safety of satralizumab for thyroid eye disease: week 24 results from the Phase 3 SatraGO-1 and SatraGO-2 randomized trials
Ophthalmology
Enspryng (satralizumab-mwge) injection: prescribing information
DailyMed, U.S. National Library of Medicine · 2026-06-22
FDA approves Genentech's Enspryng for neuromyelitis optica spectrum disorder
Genentech · 2020-08-14
Tepezza (teprotumumab-trbw) injection: prescribing information
DailyMed, U.S. National Library of Medicine · 2026-06-24
Lumvoa (veligrotug-vvze) injection: prescribing information
DailyMed, U.S. National Library of Medicine · 2026-06-29
Teprotumumab for the treatment of active thyroid eye disease (OPTIC)
New England Journal of Medicine · 2020-01-23
Teprotumumab for thyroid-associated ophthalmopathy (Phase 2)
New England Journal of Medicine · 2017-05-04
FDA approves Tepezza (teprotumumab-trbw) for the treatment of thyroid eye disease
Horizon Therapeutics via Business Wire · 2020-01-21
Promoting safe and effective drugs for 100 years (the 1962 Kefauver-Harris amendments and the substantial evidence standard)
U.S. Food and Drug Administration, FDA Consumer magazine
Demonstrating substantial evidence of effectiveness for human drug and biological products; draft guidance
Federal Register, U.S. Food and Drug Administration · 2019-12-20
Demonstrating substantial evidence of effectiveness with one adequate and well-controlled clinical investigation and confirmatory evidence; draft guidance
U.S. Food and Drug Administration
Demonstrating substantial evidence of effectiveness for human drug and biological products; revised draft guidance
Federal Register, U.S. Food and Drug Administration · 2026-06-24
Aducanumab: evidence from clinical trial data and controversies (Tampi RR, et al.)
Drugs in Context · 2021
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial
American Journal of Ophthalmology · 2018-11-01
The role of IL-6 in thyroid eye disease: an update on emerging treatments
Frontiers in Ophthalmology
Thyroid eye disease
National Organization for Rare Disorders · 2024-03-21
Viridian Therapeutics announces U.S. FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease
Viridian Therapeutics · 2026-06-26
Viridian Therapeutics announces positive topline results from REVEAL-2 Phase 3 trial of elegrobart in chronic thyroid eye disease
Viridian Therapeutics via Business Wire · 2026-05-05
Immunovant announces Phase 3 study results for batoclimab in thyroid eye disease
Immunovant
argenx provides update on UplighTED studies of efgartigimod SC in thyroid eye disease
argenx via BioSpace · 2025-12-15
Phase 3 study of linsitinib in thyroid eye disease (NCT07753603)
ClinicalTrials.gov
METEOROID: a study of satralizumab in MOG antibody-associated disease (NCT05271409)
ClinicalTrials.gov
U.S. FDA grants priority review for Genentech's Enspryng for MOG antibody-associated disease
Genentech · 2026-09-09
Genentech patient support services
Genentech
Genentech Patient Foundation
Genentech
TaggedNewsThyroid Eye DiseaseFDA DecisionEnspryngGraves' Disease

More on Trial Friend